IMNM
Immunome Inc

2,219
Mkt Cap
$2.37B
Volume
1.32M
52W High
$27.65
52W Low
$5.15
PE Ratio
-8.63
IMNM Fundamentals
Price
$20.91
Prev Close
$20.95
Open
$20.28
50D MA
$22.76
Beta
1.39
Avg. Volume
1.08M
EPS (Annual)
-$2.43
P/B
3.74
Rev/Employee
$39,214.69
$1,226.67
Loading...
Loading...
News
all
press releases
HC Wainwright Brokers Raise Earnings Estimates for Immunome
Immunome, Inc. (NASDAQ:IMNM - Free Report) - Equities researchers at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Immunome in a research report issued on Wednesday...
MarketBeat·9h ago
News Placeholder
More News
News Placeholder
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. (the Company) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 2, 2026, the...
Business Wire·24h ago
News Placeholder
HC Wainwright Analysts Boost Earnings Estimates for Immunome
Immunome, Inc. (NASDAQ:IMNM - Free Report) - Equities researchers at HC Wainwright boosted their FY2029 earnings per share estimates for Immunome in a research report issued on Wednesday, March 4th...
MarketBeat·1d ago
News Placeholder
Immunome (NASDAQ:IMNM) Price Target Raised to $36.00
Craig Hallum upped their price objective on Immunome from $33.00 to $36.00 and gave the company a "buy" rating in a research note on Wednesday...
MarketBeat·2d ago
News Placeholder
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
Key PointsSold all 3,185,000 shares of Immunome, estimated at $37.30 million based on quarterly average pricing...
Nasdaq News: Markets·2d ago
News Placeholder
Stephens Cuts Immunome (NASDAQ:IMNM) Price Target to $30.00
Stephens dropped their price objective on Immunome from $33.00 to $30.00 and set an "overweight" rating on the stock in a research note on Wednesday...
MarketBeat·2d ago
News Placeholder
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended...
Business Wire·3d ago
News Placeholder
TD Asset Management Inc Purchases 95,750 Shares of Immunome, Inc. $IMNM
TD Asset Management Inc grew its holdings in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 15.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange...
MarketBeat·3d ago
News Placeholder
Private Capital Advisors Inc. Has $1.38 Million Stake in Immunome, Inc. $IMNM
Private Capital Advisors Inc. cut its position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 37.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·8d ago
News Placeholder
Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve brokerages that are presently covering the stock, MarketBeat Ratings...
MarketBeat·11d ago
<
1
2
...
>

Latest IMNM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.